drugset / Trial / NCT02370680
Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease
Non-randomizedSingle-groupOpen-labelBasic science
Summary
This study is being conducted to evaluate the safety and the length of effect on platelet build-up in the arteries of Durlaza™ as compared to immediate-release Bayer® aspirin 81 mg or subject's current aspirin 81 mg of choice in patients who have Type 2 diabetes mellitus and cardiovascular disease or multiple risk factors of developing cardiovascular disease.
Timeline
- Start
- 2015-02
- Primary completion
- 2015-07
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | — | — |
| Subject | Aspirin | Small molecule | 81 mg | — |